FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2526843003> ?p ?o ?g. }

• W2526843003 endingPage "673" @default.
• W2526843003 startingPage "663" @default.
• W2526843003 abstract "Patients with non-small cell lung cancer (NSCLC) with mutated epidermal growth factor receptor (EGFR) are relatively sensitive to EGFR-tyrosine kinase inhibitor (TKI) treatment and have longer progression-free survival (PFS) when treated with EGFR-TKI compared with platinum-based chemotherapy. However, many patients with advanced NSCLC who have mutated EGFR do not respond to first-line EGFR-TKI treatment and still have shorter PFS.The aim of this study was to identify genetic variants associated with PFS among patients with lung adenocarcinoma who were treated with first-line EGFR-TKIs.A genome-wide association study on PFS was performed in never-smoking women diagnosed with lung adenocarcinoma and who were treated with first-line EGFR-TKIs (n = 128). Significant single-nucleotide polymorphisms (SNPs) were selected for follow-up association analysis (n = 198) and for replication assay in another independent cohort (n = 153).We identified SNPs at 4q12 associated with PFS at genome-wide significance (P < 10-8) and with an estimated hazard ratio of more than 4. This association was also replicated in a larger but similar cohort and in an independent NSCLC cohort. Follow-up functional analyses showed that these SNPs were associated with the expression of EGFR, which encodes the TKI target, and with a nearby gene neuromedin-U, which encodes a G protein-coupled receptor ligand known to be involved in the progression of NSCLC. Considering these as possible prognostic biomarkers for the treatment of patients with late-stage lung cancer, we found that these SNPs were not associated with EGFR mutation status or with polymorphism of the Bcl2-interacting mediator of cell death gene.Genetic variants in 4q12 merit further investigation to assess their potential as pharmacogenomic predictors for and to understand the biology underlying its influence on PFS in patients treated with TKI therapy." @default.
• W2526843003 created "2016-10-07" @default.
• W2526843003 creator A5005155035 @default.
• W2526843003 creator A5016184067 @default.
• W2526843003 creator A5024006617 @default.
• W2526843003 creator A5028055906 @default.
• W2526843003 creator A5028823803 @default.
• W2526843003 creator A5034220138 @default.
• W2526843003 creator A5034712963 @default.
• W2526843003 creator A5035627161 @default.
• W2526843003 creator A5041220946 @default.
• W2526843003 creator A5043010373 @default.
• W2526843003 creator A5047628204 @default.
• W2526843003 creator A5052678985 @default.
• W2526843003 creator A5054249064 @default.
• W2526843003 creator A5055074037 @default.
• W2526843003 creator A5055997007 @default.
• W2526843003 creator A5056367345 @default.
• W2526843003 creator A5059055818 @default.
• W2526843003 creator A5061928130 @default.
• W2526843003 creator A5064613277 @default.
• W2526843003 creator A5067447666 @default.
• W2526843003 creator A5073440860 @default.
• W2526843003 creator A5082822686 @default.
• W2526843003 creator A5084458604 @default.
• W2526843003 creator A5085251424 @default.
• W2526843003 creator A5087409514 @default.
• W2526843003 creator A5090036904 @default.
• W2526843003 creator A5091653870 @default.
• W2526843003 creator A5091859226 @default.
• W2526843003 date "2017-03-01" @default.
• W2526843003 modified "2023-10-18" @default.
• W2526843003 title "Genetic Modifiers of Progression-Free Survival in Never-Smoking Lung Adenocarcinoma Patients Treated with First-Line Tyrosine Kinase Inhibitors" @default.
• W2526843003 cites W1544691147 @default.
• W2526843003 cites W2014256858 @default.
• W2526843003 cites W2018838463 @default.
• W2526843003 cites W2043696829 @default.
• W2526843003 cites W2049330354 @default.
• W2526843003 cites W2051816266 @default.
• W2526843003 cites W2055243024 @default.
• W2526843003 cites W2073803740 @default.
• W2526843003 cites W2078094267 @default.
• W2526843003 cites W2078680567 @default.
• W2526843003 cites W2091091750 @default.
• W2526843003 cites W2091134276 @default.
• W2526843003 cites W2096198395 @default.
• W2526843003 cites W2101995865 @default.
• W2526843003 cites W2105311148 @default.
• W2526843003 cites W2111662961 @default.
• W2526843003 cites W2122979735 @default.
• W2526843003 cites W2129360604 @default.
• W2526843003 cites W2130254323 @default.
• W2526843003 cites W2132157071 @default.
• W2526843003 cites W2133618996 @default.
• W2526843003 cites W2139236349 @default.
• W2526843003 cites W2148514863 @default.
• W2526843003 cites W2160982674 @default.
• W2526843003 cites W2161821474 @default.
• W2526843003 cites W2161876687 @default.
• W2526843003 cites W2166084034 @default.
• W2526843003 cites W2171139285 @default.
• W2526843003 cites W2171981784 @default.
• W2526843003 cites W2915992355 @default.
• W2526843003 cites W50347796 @default.
• W2526843003 doi "https://doi.org/10.1164/rccm.201602-0300oc" @default.
• W2526843003 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5363976" @default.
• W2526843003 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27669169" @default.
• W2526843003 hasPublicationYear "2017" @default.
• W2526843003 type Work @default.
• W2526843003 sameAs 2526843003 @default.
• W2526843003 citedByCount "21" @default.
• W2526843003 countsByYear W25268430032017 @default.
• W2526843003 countsByYear W25268430032018 @default.
• W2526843003 countsByYear W25268430032019 @default.
• W2526843003 countsByYear W25268430032020 @default.
• W2526843003 countsByYear W25268430032021 @default.
• W2526843003 countsByYear W25268430032022 @default.
• W2526843003 countsByYear W25268430032023 @default.
• W2526843003 crossrefType "journal-article" @default.
• W2526843003 hasAuthorship W2526843003A5005155035 @default.
• W2526843003 hasAuthorship W2526843003A5016184067 @default.
• W2526843003 hasAuthorship W2526843003A5024006617 @default.
• W2526843003 hasAuthorship W2526843003A5028055906 @default.
• W2526843003 hasAuthorship W2526843003A5028823803 @default.
• W2526843003 hasAuthorship W2526843003A5034220138 @default.
• W2526843003 hasAuthorship W2526843003A5034712963 @default.
• W2526843003 hasAuthorship W2526843003A5035627161 @default.
• W2526843003 hasAuthorship W2526843003A5041220946 @default.
• W2526843003 hasAuthorship W2526843003A5043010373 @default.
• W2526843003 hasAuthorship W2526843003A5047628204 @default.
• W2526843003 hasAuthorship W2526843003A5052678985 @default.
• W2526843003 hasAuthorship W2526843003A5054249064 @default.
• W2526843003 hasAuthorship W2526843003A5055074037 @default.
• W2526843003 hasAuthorship W2526843003A5055997007 @default.
• W2526843003 hasAuthorship W2526843003A5056367345 @default.
• W2526843003 hasAuthorship W2526843003A5059055818 @default.
• W2526843003 hasAuthorship W2526843003A5061928130 @default.
• W2526843003 hasAuthorship W2526843003A5064613277 @default.

• next